European Prevention of Alzheimer’s Dementia (EPAD) is a new European collaborative project between academia and industry aimed at finding new treatments for alzheimer’s disease. For the first time, a large-scale individual-based characterization will enable testing and evaluation of various interventions at an early stage before symptoms occur.
This new research initiative aims to gather approximately 4,000 participants who can be quickly involved in future drug studies. A so-called adaptive study design offers an opportunity to test several different drugs at the same time and to evaluate in a short time whether a drug has the intended effect. This is a study design that is currently used successfully in cancer research.
Professor Miia Kivipelto at Karolinska Institute, is also Head of Theme Aging at Karolinska University Hospital.